

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

		1
In re application of: Serial No.:	Franklin, et al. 09/938,269 Art Unit: 1614	
Filing Date:	August 23, 2001 Examiner:	
For:	Treatment of Trauma	•
Docket No.	314572-105	
Commissioner for Par		
Washington, DC 2022	31	* *.
		ล .
Postal Service as fir	this correspondence is being deposited with the United States est-class mail in an envelope addressed to: Commissioner for n, D.C. 20231, on March 5, 2002 By: Sally B. Hansen	
<u>INFORM</u>	ATION DISCLOSURE STATEMENT UNDER 37 CFR 1	<u>.56</u>
1.	cants herein make available to the Patent and Trademark Offic	e conies o
the documents:	same never make available to the fation and frademark office	e copies é
	listed on enclosed Form PTO/SB/08A/B (Formerly PTO-144 accordance with 37 CFR 1.98(a)(2); and	•

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

Serial No. ______, filed _____

Serial No. 09/644;121, filed August 23, 2000;

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

(1)	This In	formation Disclosure Statement is being filed:
		within three months of the filing date of the patent application.
	· .	within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.
:	\square	before the mailing date of a first Office Action on the merits.
· .		after the mailing date of the first Office Action on the merits, but before the mailing date of
		a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution,
. •		and is accompanied by either:
		 □ the Statement under 37 CFR 1.97(e) (see "Statement" below), or □ the fee under 37 CFR 1.17(p).
		after the mailing date of
		a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution,,
	•	and is accompanied by both:
		the Statement under 37 CFR 1.97(e) (see "Statement" below), and the fee under 37 CFR 1.17(p).
(2)	Statem	ent
		The undersigned attorney hereby states that each item information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement. (If this box is checked, do not check any further Statement boxes.)
		or
•		The person signing immediately below hereby states that no item of information contained in the Supplemental Information Disclosure was

cited in any communication from any foreign patent office in any counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Supplemental Information Disclosure Statement.

1	the inventor(s) who sign(s) belo	337*			,		
_	the inventor(s) who sign(s) beto	w.				•	
	Signature of the Inventor(s)	, ,					
-	Typed or Printed Name of the In	ventor	(s)				
	or	•					
ve bli	a person who is substantively in esecution of the application, and whentor(s), or with the assignee, or wigation to assign the application (3 ow:	no is as ith any	socia one t	ted v o wl	with the	he here	is an
			•			₹'0,	
	Signature of the Person(s)						,
	Typed or Printed Name of the P	erson					
	4.1.1 (.1)		,	1			
	Address of Person Signing						
	Address of Person Signing						
	Address of Person Signing or		•				
		gns on	the b	asis	of the	e info	rmati
]	or	_	the b	asis	of the	e info	rmati
]	or the undersigned attorney who si	(s).					
]	or the undersigned attorney who si ☐ supplied by the inventore	(s).					
]	or the undersigned attorney who si □ supplied by the inventore □ supplied by an individua	(s).					

 $\overline{\mathbf{Q}}$

		The IDS Fee of \$180.00 under 37 CFR 1.17(p) is	enclosed he	erewith.
(5)	Method of Pa	ayment of Fees		
		Attached is a check in the amount of \$	· .	_••
•		Applicants hereby authorize the Commissioner to IDS Fee to Deposit Account No. 04-0480.	charge the	\$180.00

(6) Authorization to Charge Additional Fees

Applicants hereby authorize the Commissioner to charge any additional fees deemed required for consideration of this Paper to Deposit Account No. 04-0480.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Arthur E. Jackson
Registration No. 34,354

DECHERT P.O. Box 5218 Princeton, NJ 08543-5218 Fax: (609)620-3259

Attn: Arthur E. Jackson, Esq.

(609)620-3254

127976.1.07



Form PTO - 1449 (Modified)

U.S. Department of Commande Patent and Tracking ask Commande

Information Disclosure Statement by Applicant

(use several Sheets if necessary)

Attorney Docket No. 314572-105

|Serial No.: 09/938,269 |Applicant: Franklin, et al. |Filing Date: August 23, 2001

Group No. 1614

U.S. PATENT DOCUMENTS

	<u> </u>					
·		Issue			Sub-	Filing Date
	Patent Number	Date	Patentee	Class	Class	If Appropriate
AA	4,596,858	6/24/86	Gregor, et al.	525	328.2	\
BB	4,666,983	5/19/87	Tsubakimoto, et al.	525	119	
CC.	5,078,994	1/7/92	Nair, et al.	424	501	
DD	5,126,409	6/30/92	Jerman, et al.	525	329.9	
EE	5,229,466	7/20/93	Brehm, et al.	525	329.9	
FF	5,385,983	1/31/95	Graham	525	330.1	
GG	5,397,567	3/14/95	Lobering, et al.	424	78.04	
НН	5,455,027	10/3/95	Zalipsky, et al.	424	78.17	
Н	5,677,276	10/14/97	Dickerson, et al.	514	8	
JJ ,	5,779,696	7/14/98	Berry, et al.	606	16	
KK	5,912,228	6/15/99	Lambert, Jr.	514	12	
LL	5,942,487	8/24/99	Ogawa, et al.	514	2	
MM	6,039,940	3/21/00	Perrault, et al.	424	78.06	
NN	6,086,863	7/11/00	Ritter, et al'.	424	78.06	
	BB CC DD EE FF GG HH II JJ KK LL	AA 4,596,858 BB 4,666,983 CC 5,078,994 DD 5,126,409 EE 5,229,466 FF 5,385,983 GG 5,397,567 HH 5,455,027 II 5,677,276 JJ 5,779,696 KK 5,912,228 LL 5,942,487 MM 6,039,940	Patent Number Date AA 4,596,858 6/24/86 BB 4,666,983 5/19/87 CC 5,078,994 1/7/92 DD 5,126,409 6/30/92 EE 5,229,466 7/20/93 FF 5,385,983 1/31/95 GG 5,397,567 3/14/95 HH 5,455,027 10/3/95 II 5,677,276 10/14/97 JJ 5,779,696 7/14/98 KK 5,912,228 6/15/99 LL 5,942,487 8/24/99 MM 6,039,940 3/21/00	Patent Number Date Patentee AA 4,596,858 6/24/86 Gregor, et al. BB 4,666,983 5/19/87 Tsubakimoto, et al. CC 5,078,994 1/7/92 Nair, et al. DD 5,126,409 6/30/92 Jerman, et al. EE 5,229,466 7/20/93 Brehm, et al. FF 5,385,983 1/31/95 Graham GG 5,397,567 3/14/95 Lobering, et al. HH 5,455,027 10/3/95 Zalipsky, et al. II 5,677,276 10/14/97 Dickerson, et al. JJ 5,779,696 7/14/98 Berry, et al. KK 5,912,228 6/15/99 Lambert, Jr. LL 5,942,487 8/24/99 Ogawa, et al. MM 6,039,940 3/21/00 Perrault, et al.	Patent Number Date Patentee Class AA 4,596,858 6/24/86 Gregor, et al. 525 BB 4,666,983 5/19/87 Tsubakimoto, et al. 525 CC 5,078,994 1/7/92 Nair, et al. 424 DD 5,126,409 6/30/92 Jerman, et al. 525 EE 5,229,466 7/20/93 Brehm, et al. 525 FF 5,385,983 1/31/95 Graham 525 GG 5,397,567 3/14/95 Lobering, et al. 424 HH 5,455,027 10/3/95 Zalipsky, et al. 424 II 5,677,276 10/14/97 Dickerson, et al. 514 JJ 5,779,696 7/14/98 Berry, et al. 606 KK 5,912,228 6/15/99 Lambert, Jr. 514 LL 5,942,487 8/24/99 Ogawa, et al. 514 MM 6,039,940 3/21/00 Perrault, et al. 424	Patent Number Date Patentee Class Class AA 4,596,858 6/24/86 Gregor, et al. 525 328.2 BB 4,666,983 5/19/87 Tsubakimoto, et al. 525 119 CC 5,078,994 1/7/92 Nair, et al. 424 501 DD 5,126,409 6/30/92 Jerman, et al. 525 329.9 EE 5,229,466 7/20/93 Brehm, et al. 525 329.9 FF 5,385,983 1/31/95 Graham 525 330.1 GG 5,397,567 3/14/95 Lobering, et al. 424 78.04 HH 5,455,027 10/3/95 Zalipsky, et al. 424 78.17 II 5,677,276 10/14/97 Dickerson, et al. 514 8 JJ 5,779,696 7/14/98 Berry, et al. 606 16 KK 5,912,228 6/15/99 Lambert, Jr. 514 2 MM 6,039,940 3/21/00

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Exmr Initial	-	Document Number	Publn Date*	Country or Patent Office	Class	Sub- Class	Translat Yes	on? No
	٠	WO 98/26789	6/25/98	PCT	i			
		WO 99/38472	8/5/99	PCT	:			•
			,					, .

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Place of Publication**)

				·	
				•	
			· · · · · · · · · · · · · · · · · · ·		
,					
Examir	ner			Date Considered	
		*			
<u> </u>					

127975.1.07

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form.PTO - 2)

^{*} Use publication date indicated on the patent or published application. 37 CFR 1.98(b).

^{**} The place or publication refers to the name of the journal, magazine or other publication

Form PTO - 1449 U.S. Department of Recommendation (Modified)

Patent and Trademark Office

ent and Trademark Office | Serial No.: 09/644,121

Information Disclosure Statement by Applicant

(use 'several Sheets if necessary)

|Serial No.: 09/644,121 |Applicant: Hubbell et al. |Filing Date: August 23, 2000 |Group No. Not Yet Assigned

Attorney Docket No. 314572-103 C

U.S. PATENT DOCUMENTS

Exmr		Issue			Sub-	Filing Date
Initial	Patent Number	Date	Patentee	Class	Class	If Appropriate
AA	5,939,208	8/17/99	Stoy			
BB	5,423,736	6/13/95	Cartmell et al.		•	
CC	5,306,504	4/26/94	Lorenz			
DD	5,204,110	4/20/93	Cartmell et al.		•	
EE	5,160,328	11/3/92	Cartmell et al.			
FF	5,154,706	10/13/92	Cartmell et al.	,		
GG	5,920,158	7/6/99	Miller et al.		•	
HH	5,705,177	1/6/98	Roufa et al.			•
11	5,705,178	1/6/98	Roufa et al.			
JJ	5,080,893	1/14/92	Goldberg et al.			• "
KK	6,010,692	1/4/00	Goldberg et al.			
LL	5,885,566	3/23/99	Goldberg			
MM	5,665,477	9/9/97	Meathrel et al.			
NN	5,350,573	9/27/94	Goldberg et al.			
00	5,140,016	8/18/92	Goldberg et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Exmr	Document Number	Publn			Sub-	Translation?
Initial		Date*	Country or Patent	Class	Class	Yes No
			Office			
PP	EP 0952171A2	10/27/99	Europe			
QQ	WO 97/05185	2/13/97	PCT			
RR	WO 99/44557	9/10/99	PCT			
SS	WO 99/47129	9/23/99	PCT			
TT	WO 95/15352	6/8/95	PCT			
· UU	EP 0604101A1	12/14/93	Europe			
VV	WO 92/06748	4/30/92	PCT			
WW	EP 0426422A2	10/30/90	Europe			
XX	EP 0068509B1	8/25/85	Europe			
YY	WO 00/44808	8/3/00	PCT			
ZZ	JP262249	10/7/97	Japan			No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Place of Publication**)

AB		Fate of Water-Soluble Polymers Administered via Different Routes, Tetsuji et al.; J of
	ŀ	Pharm. Sci Vol. 84, No. 3, March 1995 Pg. 349-354.

Examiner	 		Date Considered	
			_	
		·	1	•

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 2)

- Use publication date indicated on the patent or published application. 37 CFR 1.98(b). The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.

96298.1.07